Bromo-DragonFLY is known to produce increased heart rate, a physical effect. A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a forceful, rapid pounding felt throughout the chest, neck, and temples. This effect is among the most commonly reported physiological responses to psychoactive substances and often accompanies stimulation, anxiety, or physical exertion during intoxication.
Increased heart rate, clinically termed tachycardia when exceeding 100 beats per minute at rest, manifests as a heightened awareness of one's own cardiac rhythm. At lower intensities, users may simply notice their pulse feels slightly faster than baseline—a faint thumping sensation in the chest or a mild warmth spreading through the torso. At higher intensities, the heartbeat becomes impossible to ignore: a powerful, rapid drumming that can be felt in the throat, wrists, and behind the eyes, sometimes accompanied by visible pulsation of veins and a sensation of the heart "trying to escape" the ribcage.
The intensity of this effect follows a clear dose-dependent curve. At threshold doses of stimulants or psychedelics, heart rate may increase by only 5-15 BPM above baseline—barely perceptible without deliberately checking one's pulse. At moderate doses, increases of 20-40 BPM become noticeable during both activity and rest, often accompanied by a subtle chest tightness. At high doses or during combinations, heart rate can spike to 140-180+ BPM, producing significant discomfort, breathlessness, and anxiety that may trigger panic responses that further compound the tachycardia.
Several distinct subtypes exist. Stimulant-induced tachycardia tends to feel "electric" and buzzing, as if the heart is running at high RPM but smoothly. Psychedelic tachycardia is often intermittent and closely tied to emotional state—surges of awe or anxiety produce momentary spikes. Cannabinoid-induced increases feel more diffuse and are frequently accompanied by postural hypotension. Dissociative tachycardia is often less consciously noticed due to the analgesic and detaching properties of these substances, making it particularly insidious.
Pharmacologically, increased heart rate results from several mechanisms: direct sympathomimetic activation (as with amphetamines and cocaine, which increase catecholamine release), vagal nerve suppression (as with anticholinergic compounds), peripheral vasodilation triggering baroreceptor-mediated compensatory tachycardia (as with cannabis and some psychedelics), or direct agonism at cardiac beta-adrenergic receptors. Serotonergic compounds can also produce tachycardia via 5-HT2A and 5-HT2B receptor activation.
This effect is most prominently associated with stimulants (amphetamines, cocaine, MDMA, caffeine), but it is also common with psychedelics (LSD, psilocybin, mescaline), cannabinoids (THC), dissociatives (PCP, ketamine at higher doses), and empathogens. Essentially, any substance that activates the sympathetic nervous system or suppresses parasympathetic tone can produce it.
From a harm reduction perspective, increased heart rate becomes dangerous when sustained at very high levels, in individuals with pre-existing cardiac conditions, or when combined with other cardiotoxic substances. The combination of stimulants with MAOIs or other stimulants poses particular risk for hypertensive crisis. Users experiencing tachycardia should avoid further stimulant intake, remain hydrated, practice slow breathing techniques, and seek medical attention if heart rate exceeds 150 BPM at rest or is accompanied by chest pain, irregular rhythm, or difficulty breathing.
Increased heart rate can manifest at varying intensities depending on the dose of Bromo-DragonFLY and individual sensitivity. The following levels describe the typical progression of this effect.
A subtle awareness of one's heartbeat, only noticeable when paying attention. Heart rate increased by 5-15 BPM above baseline.
Heart rate is clearly elevated and noticeable during rest. Mild warmth in the chest. Increase of 15-30 BPM.
A pronounced, forceful heartbeat felt in the chest, neck, and wrists. Accompanied by mild breathlessness. Increase of 30-50 BPM.
Rapid, pounding heartbeat that dominates body awareness. Visible pulsation in veins. Accompanied by anxiety and chest tightness. 50-70+ BPM above baseline.
An extremely rapid, forceful heartbeat exceeding 150 BPM at rest. May feel chaotic or irregular. Accompanied by significant distress, breathlessness, and potential medical danger.
The hallucinogenic effect of bromo-DragonFLY is mediated by its agonist activity at the 5-HT2A serotonin receptor. Bromo-DragonFLY also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptors, and is most accurately described as a non-subtype selective 5-HT2 agonist, as it is actually twice as potent an agonist for 5-HT2C receptors as for 5-HT2A, as well as being less than 5x selective for 5-HT2A over 5-HT2B.
It is further suggested that Bromo-DragonFLY almost completely inhibits MAO-A activity, which makes itself unable to metabolize. This is probably the cause for an abnormal duration of action.
However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Compared to LSD, this compound presents a significantly less pronounced body high, reduced visual effects and more in-depth hallucinations which are comparable to mescaline or 2C-B. Despite the visual and physical effects, it reportedly tends to maintain a level of sober thought structure. As the user usually retains acute cognitive sobriety, Bromo-DragonFLY can be considered to have diminished effects of confusion and potential delusions when compared to 4-AcO-DMT, psilocin, or LSD.
Bromo-DragonFLY can be considered extremely toxic at very high dosages with several deaths and numerous hospitalizations reported on overdoses. It can also have vasoconstrictive effects]], which can result in severe tissue damage or even limb amputation. Due to its high potency,one can easily overdose if this substance is not measured correctly ("eyeballed") or mislabeled as another substance.
The toxicity and long-term health effects of recreational Bromo-toxic dose is unknown. This is because Bromo-DragonFLY is a research chemical with very little history of human usage.
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.
On May 7, 2011, in the United States, two young adults died and several others were hospitalized after overdosing on Bromo-DragonFLY, which they believed was 2C-E.
Bromo-not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of Bromo-almost immediately after ingestion. After that,614 days to be back at baseline (in the absence of further consumption). Bromo-DragonFLY presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of Bromo-DragonFLY all psychedelics will have a reduced effect.
The risk of Bromo-DragonFLY overdose is unknown at the time, suggesting that there may not be a safe dosage. Non-oral routes also seem to exhibit a higher chance of overdosing, perhaps owing to differences in bioavailability, potency and unpredictability of dosage and effects. Overdose effects of typically include bizarre, delusional and sometimes violent behavior, amnesia, numbness, confusion and anxiety. The user may not be able to communicate and can be severely agitated. At appropriately high doses, more severe side effects include panic attacks, seizures, dangerously prolonged elevated heart rate, blood pressure and vasoconstriction. Vasoconstriction typically develops to its peak several hours into the intoxication and will need medical assistance since Bromo-DragonFLY is known to do this for an extremely long time.
The abnormally long duration of Bromo-DragonFLY poses a significant risk by staying inside the body for weeks.
In the event of an overdose, benzodiazepines can be administered to mitigate the hyper-agitative effects. A potent vasodilator will need to be continuously administered to prevent a hypertensive emergency, necrosis, organ failure and death from the resulting hypoxia. As a result, emergency medical services should always be sought in the event of an overdose.
Australia:** Bromo-DragonFLY is nationally a Schedule 9 substance, making it illegal to possess, produce and sell.
Canada:** Bromo-DragonFLY was listed as a Schedule III Substance as of October 12, 2016, along several other research chemicals.
Denmark:** Possession, production and sale is illegal.
Finland:** Possession, production and sale is illegal.
Germany:** Bromo-DragonFLY is controlled under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
Japan: Bromo-DragonFLY is a controlled substance in Japan effective August 19th, 2015.
Norway:** Bromo-DragonFLY is considered a narcotic in Norway.
Romania:** Possession, production and sale is illegal.
Sweden:** Bromo-DragonFLY is listed as a Schedule IV substance, making it illegal to possess, produce and sell.
Switzerland: Bromo-DragonFLY is likely illegal in Switzerland. It is unclear whether Bromo-DragonFLY is in the scope of a substituted a-methylphenethylamine under Verzeichnis E point 130, since it is not an "alkyl, alkoxy, alkylenedioxy or halide derivative of phenethylamine", while additionally containing further univalent substituents, according to the scope. It is also unclear if it can be considered a true ether analog of an ether analog of DOB, which would make it controlled under Buchstabe C. It could be considered an ether analog of an ether analog of para-bromoamphetamine, which would also make it illegal under Buchstabe C, but the extent of all these definitions are unknown.
Turkey:** Bromo-DragonFLY is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom** - It is illegal to produce, supply, or import this substance under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Bromo-DragonFLY is listed as a Schedule I substance in Oklahoma.The Oklahoman, "https://www.oklahoman.com/story/news/crime/2012/08/13/man-sentenced-in-2011-designer-drug-deaths-of-two-oklahoma-college-students/61052749007/ Man sentenced in 2011 designer drug deaths of two Oklahoma college students"
Responsible use
Volumetric dosing
Research chemicals
Substituted phenethylamines
Bromo-DragonFLY (Wikipedia)
Bromo-DragonFLY (Erowid Vault)
Bromo-DragonFLY (Isomer Design)
Bromo-DragonFLY (Drugs-Forum)
Bromo-DragonFLY can be administered via oral. The route of administration can influence both the onset and intensity of increased heart rate.
The intensity of increased heart rate depends heavily on the dose of Bromo-DragonFLY. Effects like increased heart rate are typically reported at common to strong doses. Below is the full dosage chart for Bromo-DragonFLY.
Warning
Sustained heart rates above 150 BPM can strain the cardiovascular system and may trigger arrhythmias in susceptible individuals. This effect is particularly dangerous when combining stimulants, in people with pre-existing heart conditions, or with substances that prolong the QT interval. Seek medical attention for chest pain, irregular rhythm, or sustained extreme tachycardia.
Yes. Increased heart rate is a documented physical effect of Bromo-DragonFLY. A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a forceful, rapid pounding felt throughout the chest, neck, and temples. This effect is among the most commonly reported physiological responses to psychoactive substances and often accompanies stimulation, anxiety, or physical exertion during intoxication.
Effects like increased heart rate are typically reported at common doses and above. A common oral dose of Bromo-DragonFLY is 300–500 µg.
Other substances documented to produce increased heart rate include Amphetamine, Cocaine, MDMA, Cannabis, Caffeine, and 35 more.